person

Elmar S.

Country
Germany
Department
Klinik für Gynäkologie und Geburtsmedizin

Research Overview

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
424
Sites with multiple studies

Has run more than one trial at 424 of 744 partner sites.

Specializations

Hormone Receptor-Positive Breast Cancer

The investigator specializes in treating HR+/HER2- early breast cancer through innovative therapeutic approaches. Their research encompasses the evaluation of novel treatment combinations involving endocrine therapy with targeted agents.

  • Adjuvant therapy optimization
  • CDK4/6 inhibitor treatments
  • Extended endocrine therapy strategies

Their work includes personalized therapeutic approaches and dynamic marker-adjusted treatment protocols.

HER2-Positive Breast Cancer

The investigator focuses on advancing treatment protocols for HER2-positive early breast cancer. Their research examines innovative targeted therapies and antibody-drug conjugates in the neoadjuvant setting.

  • Neoadjuvant treatment strategies
  • Novel antibody-drug conjugates
  • Pathologic response assessment

Their expertise includes evaluating treatment outcomes and long-term survival metrics.

Triple-Negative and High-Risk Breast Cancer

The investigator conducts research in treating triple-negative breast cancer and high-risk breast cancer variants. Their work includes studies of immunotherapy combinations and targeted approaches for specific genetic mutations.

  • Immunotherapy integration
  • BRCA-mutated breast cancer
  • Novel therapeutic combinations

Their research addresses treatment strategies for aggressive disease subtypes.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.